Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M. Nüßlein HG, et al. Among authors: alten r. BMC Musculoskelet Disord. 2015 Jul 30;16:176. doi: 10.1186/s12891-015-0636-9. BMC Musculoskelet Disord. 2015. PMID: 26228643 Free PMC article.
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J. Braun J, et al. Among authors: alten r. Rheumatology (Oxford). 2005 May;44(5):670-6. doi: 10.1093/rheumatology/keh584. Epub 2005 Mar 9. Rheumatology (Oxford). 2005. PMID: 15757965 Clinical Trial.
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J. Baraliakos X, et al. Among authors: alten r. Arthritis Res Ther. 2005;7(3):R439-44. doi: 10.1186/ar1693. Epub 2005 Feb 21. Arthritis Res Ther. 2005. PMID: 15899030 Free PMC article. Clinical Trial.
Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis.
Díaz-González F, Alten RH, Bensen WG, Brown JP, Sibley JT, Dougados M, Bombardieri S, Durez P, Ortiz P, de-Miquel G, Staab A, Sigmund R, Salin L, Leledy C, Polmar SH. Díaz-González F, et al. Among authors: alten rh. Ann Rheum Dis. 2007 May;66(5):628-32. doi: 10.1136/ard.2006.062554. Epub 2006 Dec 14. Ann Rheum Dis. 2007. PMID: 17170051 Free PMC article. Clinical Trial.
[Current therapeutic strategy for rheumatoid arthritis].
Wollenhaupt J, Alten R, Burkhardt H, Edelmann E, Gromnica-Ihle E, Krause A, Krüger K, Manger B, Lorenz H, Müller-Ladner U, Nüsslein H, Pott HG, Tony H, Schneider M. Wollenhaupt J, et al. Among authors: alten r. MMW Fortschr Med. 2006 Oct 19;148(42):38-42; quiz 43. MMW Fortschr Med. 2006. PMID: 17621798 German.
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J. Braun J, et al. Among authors: alten r. Ann Rheum Dis. 2008 Mar;67(3):340-5. doi: 10.1136/ard.2007.075879. Epub 2007 Oct 29. Ann Rheum Dis. 2008. PMID: 17967831 Free article. Clinical Trial.
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.
Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman M, Toloza S, Pincus T; QUEST-RA Group. Naranjo A, et al. Arthritis Res Ther. 2008;10(2):R30. doi: 10.1186/ar2383. Epub 2008 Mar 6. Arthritis Res Ther. 2008. PMID: 18325087 Free PMC article.
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.
Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T. Alten R, et al. Arthritis Res Ther. 2008;10(3):R67. doi: 10.1186/ar2438. Epub 2008 Jun 5. Arthritis Res Ther. 2008. PMID: 18534016 Free PMC article. Clinical Trial.
233 results